Publications & Evidence
Explore peer-reviewed research and scientific publications that highlight the urgent need for better Lyme disease diagnostics and support the development of LYMESEEK™, Aces Diagnostics’ advanced diagnostic solution.
Tick Season Is Back—And So Is Hope for a New Lyme Treatment
Medscape, May 2024
This article highlights renewed urgency in improving Lyme disease care as tick season intensifies across the U.S. It discusses upcoming advancements in treatment and underscores persistent gaps in early detection—gaps that LymeSeek aims to fill. As current diagnostics frequently miss early infections, LymeSeek’s enhanced sensitivity addresses this critical need by enabling earlier, more accurate diagnosis—ultimately improving patient outcomes and guiding timely treatment.
Lyme Disease and Reproductive Health
LymeDisease.org, 2024
This article sheds light on the potential effects of Lyme disease on reproductive health, including concerns around pregnancy, miscarriage, and congenital transmission. It calls attention to the lack of definitive research and the limitations of current testing methods. By offering greater accuracy and earlier detection, LymeSeek may play a pivotal role in helping individuals make more informed reproductive health decisions and reducing the risks associated with undiagnosed infections.
Evaluation of Serologic Tests for Lyme Borreliosis in Europe
European Journal of Clinical Microbiology & Infectious Diseases, October 2024
This comprehensive study evaluated the effectiveness of standard two-tier testing (STTT) for diagnosing Lyme borreliosis in over 1,800 patients across Europe. The researchers found that STTT had a sensitivity of just 50% in detecting early Lyme disease, such as cases presenting with erythema migrans (EM)—a common early symptom in European strains of Lyme. Notably, European Borrelia strains more consistently cause EM rashes than U.S. strains, making these cases easier to identify clinically.
Despite this clinical advantage, half of early Lyme cases still went undetected by STTT, emphasizing a major limitation in current diagnostic methods—even in symptom-visible scenarios. The study underscores the need for more sensitive and reliable diagnostic tools, particularly for early-stage Lyme when timely treatment is most effective.
These findings support the mission of LymeSeek to deliver innovative testing that can detect Lyme disease accurately in its earliest stages—before it progresses and becomes harder to treat.
New Study Shows Less Than One-Third of Lyme Disease Test Results Are Accurate For Patients With Lyme Rash
Illinois Lyme Association, January 2020
This study published in the Journal of Clinical Microbiology evaluated 75 participants with physician-diagnosed Lyme disease and erythema migrans (EM), the hallmark bull’s-eye rash. The CDC's standard two-tier testing algorithm (STTTA) correctly identified only 29% (22 of 75) of these early Lyme cases.
When comparing detection rates:
-
STTTA identified just 29% of EM-confirmed Lyme cases.
-
A single-tier test using the C6 peptide ELISA showed higher sensitivity, correctly identifying 44 of 75 cases (59%).
These results highlight the critical limitations of current testing protocols, particularly in early-stage Lyme disease when timely diagnosis is essential for effective treatment. The findings reinforce the need for more accurate diagnostic tools—such as LymeSeek—that can detect Lyme disease earlier and more reliably.